Propranolol in the treatment of infantile haemangiomas: lessons from the European Propranolol In the Treatment of Complicated Haemangiomas (PITCH) Taskforce survey
- 16 October 2015
- journal article
- research article
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 174 (3), 594-601
- https://doi.org/10.1111/bjd.14233
Abstract
Background Oral propranolol is widely prescribed as first‐line treatment for infantile haemangiomas (IHs). Anecdotally, prescribing practice differs widely between centres. Objectives The Propranolol In the Treatment of Complicated Haemangiomas (PITCH) Taskforce was founded to establish patterns of use of propranolol in IHs. Methods Participating centres entered data on all of their patients who had completed treatment with oral propranolol for IHs, using an online data capture tool. Results The study cohort comprised 1097 children from 39 centres in eight European countries. 76·1% were female and 92·8% had a focal IH, with the remainder showing a segmental, multifocal or indeterminate pattern. The main indications for treatment were periocular location (29·3%), risk of cosmetic disfigurement (21·1%) and ulceration and bleeding (20·6%). In total 69·2% of patients were titrated up to a maintenance regimen, which consisted of 2 mg kg−1 per day (85·8%) in the majority of cases. 91·4% of patients had an excellent or good response to treatment. Rebound growth occurred in 14·1% upon stopping, of whom 53·9% were restarted and treatment response was recaptured in 91·6% of cases. While there was no significant difference in the treatment response, comparing a daily maintenance dose of < 2 mg kg−1 vs. 2 mg kg−1 vs. > 2 mg kg−1, the risk of adverse events was significantly higher: odds ratio (OR) 1 vs. adjusted OR 0·70, 95% confidence interval (CI) 0·33–1·50, P = 0·36 vs. OR 2·38, 95% CI 1·04–5·46, P = 0·04, Ptrend < 0·001. Conclusions The PITCH survey summarizes the use of oral propranolol across 39 European centres, in a variety of IH phases, and could be used to inform treatment guidelines and the design of an interventional study.Keywords
This publication has 27 references indexed in Scilit:
- Propranolol in a case series of 174 patients with complicated infantile haemangioma: indications, safety and future directionsBritish Journal of Dermatology, 2013
- Use of propranolol for treatment of infantile haemangiomas in an outpatient settingJournal of Paediatrics and Child Health, 2012
- A Randomized Controlled Trial of Propranolol for Infantile HemangiomasPublished by American Academy of Pediatrics (AAP) ,2011
- Do we have to check glucose in patients with haemangioma of infancy treated with beta-blockers?Journal of the European Academy of Dermatology and Venereology, 2011
- Oral Propranolol Therapy for Infantile Hemangiomas Beyond the Proliferation Phase: A Multicenter Retrospective StudyPediatric Dermatology, 2011
- Propranolol for complicated infantile haemangiomas: a case series of 30 infantsBritish Journal of Dermatology, 2010
- Research electronic data capture (REDCap)—A metadata-driven methodology and workflow process for providing translational research informatics supportJournal of Biomedical Informatics, 2008
- Propranolol for Severe Hemangiomas of InfancyNew England Journal of Medicine, 2008
- Prospective Study of Infantile Hemangiomas: Demographic, Prenatal, and Perinatal CharacteristicsThe Journal of Pediatrics, 2007
- Ulcerated hemangiomas: Clinical characteristics and response to therapyJournal of the American Academy of Dermatology, 2001